sorafenib has been researched along with arq 197 in 6 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (arq 197) | Trials (arq 197) | Recent Studies (post-2010) (arq 197) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 109 | 39 | 106 |
Protein | Taxonomy | sorafenib (IC50) | arq 197 (IC50) |
---|---|---|---|
Hepatocyte growth factor receptor | Homo sapiens (human) | 0.36 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 6 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Guo, M; He, J; Jiang, X; Jiang, Y; Li, J; Liu, J; Ouyang, L; Wang, J; Zhang, J; Zhang, S | 1 |
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
Adjei, AA; Chai, F; Dy, GK; Goff, L; Lamar, M; Ma, WW; Martell, R; Means-Powell, JA; Puzanov, I; Saif, MW; Santoro, A; Savage, RE; Schwartz, B; Simonelli, M; Sosman, J; Zucali, P | 1 |
Colquhoun, S; Hata, K; Hoon, DS; Hoshino, H; Huang, SK; Iida, Y; Ohta, K; Ono, S; Wang, J | 1 |
Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A | 1 |
Best, J; Dechêne, A; Gerken, G; Lohmann, G; Schotten, C | 1 |
3 review(s) available for sorafenib and arq 197
Article | Year |
---|---|
Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
Topics: Antineoplastic Agents; Drug Discovery; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridines; Quinazolines; Quinolones; Receptors, Vascular Endothelial Growth Factor; Small Molecule Libraries | 2016 |
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Tivantinib for the treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Sorafenib | 2017 |
1 trial(s) available for sorafenib and arq 197
Article | Year |
---|---|
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 CYP2C19; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Sorafenib; Treatment Outcome; Young Adult | 2015 |
2 other study(ies) available for sorafenib and arq 197
Article | Year |
---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Apoptosis; Binding Sites; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinase; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Pyrrolidinones; Quinolines; Sorafenib; Time Factors; Transfection; Up-Regulation | 2015 |